The filing is a routine investor presentation with no new material financial disclosures or catalysts. Monitor for partnership announcements for IMM-529 or IMM-124E, which could be significant value drivers. The company's cash runway of ~22.5 months supports operations without near-term financing pressure.
Price Chart
Executive Summary
Immuron Ltd filed a 6-K containing an investor presentation from CEO Steven Lydeamore at a Kalkine Media Webinar. The presentation reports FY26 global sales revenue of A$7.7 million (+6% YoY), with Australian sales up 10% and US sales up 13% in USD. The company reiterated its strategic decision to partner its clinical assets (IMM-124E and IMM-529) for development and commercialization, and highlighted cash of A$10.0 million. No new material financial guidance or catalysts were disclosed.
Key Facts
- FY26 global sales revenue of A$7.7 million, up 6% on prior year
- FY26 Australian sales A$5.8 million, up 10% YoY
- FY26 US sales A$1.8 million, up 7% (13% in USD)
- Cash of A$10.0 million as of 31 December 2025
- Strategic decision to partner IMM-124E (Travelan) and IMM-529 (C. diff) for development and commercialization
- EBITDX (ex-R&D) for HY26 was -A$1.1 million
Financial Impact
FY26 global sales A$7.7M (+6% YoY); cash A$10.0M; EBITDX (ex-R&D) -A$1.1M in HY26
Risk Factors
- Clinical development risks for IMM-529 and IMM-124E
- Partnership execution and timing uncertainty
- Cash burn from R&D and commercial operations
- Small market cap ($10M) and low trading liquidity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-079406 |
| Document: ea0298506-6k_immuron.htm | 0001213900-26-079406 |
| Document: 0001213900-26-079406-index-headers.html | 0001213900-26-079406 |
| Document: 0001213900-26-079406-index.html | 0001213900-26-079406 |
| Document: 0001213900-26-079406.txt | 0001213900-26-079406 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $0.9300 | awaiting T+60 | — | $0.9300 (+0.00%) |
Oct 23, 2026 4d ago | 6-K | $0.9200 | awaiting T+60 | — | $0.9300 (+1.09%) |
Oct 23, 2026 4d ago | 424B5 | $0.9200 | awaiting T+60 | — | $0.9300 (+1.09%) |
Oct 21, 2026 6d ago | 6-K | $0.9490 | awaiting T+60 | — | $0.9300 (−2.00%) |
Oct 16, 2026 11d ago | 6-K | $0.9821 | awaiting T+60 | — | $0.9300 (−5.30%) |
Oct 13, 2026 14d ago | 6-K | $1.04 | awaiting T+60 | — | $0.9300 (−10.58%) |
Sep 24, 2026 4w ago | 20-F | $1.19 | awaiting T+60 | — | $0.9300 (−21.85%) |
Sep 24, 2026 4w ago | 6-K | $1.19 | awaiting T+60 | — | $0.9300 (−21.85%) |
Sep 21, 2026 5w ago | 6-K | $1.26 | awaiting T+60 | — | $0.9300 (−25.90%) |
Sep 4, 2026 7w ago | Press Release | $1.80 | awaiting T+60 | — | $0.9300 (−48.33%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers